IFITM3P2: A Potential Drug Target and Biomarker (G144383)

Target Name: IFITM3P2

NCBI ID: G144383

IFITM3P2

Other Name(s): Interferon induced transmembrane protein 3 pseudogene | DSPA2D | IFITM3 pseudogene 2

IFITM3P2: A Potential Drug Target and Biomarker

Introduction

Interferon-induced transmembrane protein 3 (IFITM3P2) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. IFITM3P2 is a transmembrane protein that is expressed in various tissues and cells in the body, including the liver, pancreas, and blood cells. It is characterized by its extracellular domain, which is composed of a farnesylated cysteine 鈥嬧?媟esidue and a long amino acid sequence, as well as its intracellular domain, which is composed of a single amino acid residue.

IFITM3P2 has also been shown to be involved in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders..

As a Potential Drug Target

IFITM3P2 has been identified as a potential drug target due to its involvement in various diseases.IFITM3P2 has been shown to be involved in the development and progression of cancer, including melanoma, lung cancer, and liver cancer.IFITM3P2 has also been shown to be involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. IFITM3P2 has also been shown to be involved in the development and progression of autoimmune disorders, including rheumatoid arthritis and multiple sclerosis.

IFITM3P2 is also a good candidate for a biomarker in these diseases because of its expression in various tissues and cells, as well as its potential to be used as a therapeutic target. IFITM3P2 has been shown to be expressed in various tissues and cells, including the liver, pancreas, and blood cells, which makes it a potential biomarker for these diseases. IFITM3P2 has also been shown to be involved in the development and progression of cancer, which makes it a potential drug target for these diseases.

IFITM3P2 is also a good candidate for a biomarker in these diseases because of its expression in various tissues and cells, as well as its potential to be used as a therapeutic target. IFITM3P2 has been shown to be expressed in various tissues and cells, including the liver, pancreas, and blood cells, which makes it a potential biomarker for these diseases. IFITM3P2 has also been shown to be involved in the development and progression of cancer, which makes it a potential drug target for these diseases.

IFITM3P2 is a transmembrane protein that has been shown to play a role in various cellular processes, including cell signaling, DNA replication, and cell survival.IFITM3P2 has also been shown to be involved in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

IFITM3P2 has been identified as a potential drug target and biomarker due to its involvement in these diseases.IFITM3P2 is a transmembrane protein that has been shown to play a role in various cellular processes, including cell signaling, DNA replication, and cell survival.IFITM3P2 has has also been shown to be involved in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Protein Name: IFITM3 Pseudogene 2

The "IFITM3P2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IFITM3P2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets